| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 10,882 | 10,052 | 11,832 | 10,418 |
| Provision (benefit) for credit losses | -931 | 761 | -1,465 | 1,385 |
| Loss on impairment of intangibles assets | 209 | 0 | - | - |
| Loss on disposal of inventory | 314 | - | - | - |
| Interest expense | 1,179 | 1,155 | 1,130 | 1,139 |
| Pharmaceutical manufacturing, research and development expense | 147 | 645 | 758 | 585 |
| Change in fair value of acquisition-related contingent consideration | 0 | 0 | - | - |
| Depreciation and amortization expense | 2 | 19 | 19 | 234 |
| General and administrative expense | 3,286 | 2,843 | 3,277 | 2,993 |
| Income from operations | 6,676 | 4,629 | 8,113 | 4,082 |
| Unrealized net (loss) gain on marketable investments | - | - | - | -6 |
| Unrealized net gains on warrants | 2,640 | 347 | -424 | 47 |
| Net gain on exercise and cancellation of warrants | 0 | 0 | - | - |
| Loss on sale of assets | 0 | 0 | -82 | - |
| Discontinued operation, gain (loss) on disposal of discontinued operation, net of tax | 1,601 | - | - | - |
| Net loss on marketable investments | -246 | 37 | -105 | - |
| Realized gain on early payment of finance receivable | 0 | 0 | 1,729 | - |
| Gain (loss) on revaluation of finance receivables | 0 | 0 | -3,727 | - |
| Realized and unrealized foreign currency transaction gains (losses) | 25 | -451 | 313 | 251 |
| Income before income tax expense | 10,696 | 4,562 | 5,817 | 4,374 |
| Income tax expense | 1,916 | 1,026 | 1,278 | 906 |
| Net income | 8,780 | 3,536 | 4,539 | 3,468 |
| Basic (in dollars per share) | 0.72 | 0.29 | 0.37 | 0.28 |
| Basic (in shares) | 12,117,000 | 12,208,000 | 12,229,000 | 12,318,000 |
| Diluted (in dollars per share) | 0.72 | 0.29 | 0.37 | 0.28 |
| Diluted (in shares) | 12,117,000 | 12,208,000 | 12,240,000 | 12,408,000 |
SWK Holdings Corp (SWKH)
SWK Holdings Corp (SWKH)